Live News EQUITY FLASH L impact Oct 15, 2026, 08:05 PM UTC MacroGenics doses first patient in MGC030 Phase 1 study The Phase 1 study is evaluating MGC030 in patients with advanced solid tumors. MGNX SquawkNews Desk